Trials
1 active
12 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Oral Mucositis
- Main trialPhase 2
- “The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients will receive RRx-001 or placebo before start of standard of care treatment.”In the company’s words, NCT05966194 on ClinicalTrials.gov
Coming up1
- 1 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 1 Jul 2027 | RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer | |
| Phase 3Terminated | 11 Aug 2022 | RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer | |
| Phase 3Unknown | 31 Dec 2025 | A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer | |
| Phase 2Terminated | 10 May 2016 | RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy | |
| Phase 2Completed | 13 Apr 2018 | A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer | |
| Phase 2Completed | 22 Oct 2019 | Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers | |
| Phase 2Completed | 6 Dec 2021 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | |
| Phase 1Completed | Feb 2015 | Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects | |
| Phase 1Completed | 28 Nov 2016 | Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases | |
| Phase 1Terminated | 22 Nov 2018 | RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) | |
| Phase 1Completed | 11 Oct 2019 | RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas | |
| Phase 1Terminated | 29 Jul 2024 | RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026